Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.

D Noël; M Pelegrin; F Brockly; Anders Henrik Lund; M Piechaczyk

doi:10.1046/j.1523-1747.2000.00106.x

Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.

D Noël, M Pelegrin, F Brockly, Anders Henrik Lund, M Piechaczyk

15 Citations (Scopus)

Abstract

In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.

Original language	English
Journal	Journal of Investigative Dermatology
Volume	115
Issue number	4
Pages (from-to)	740-5
Number of pages	5
ISSN	0022-202X
DOIs	https://doi.org/10.1046/j.1523-1747.2000.00106.x
Publication status	Published - 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1046/j.1523-1747.2000.00106.x

Cite this

@article{c96ad7b0702b11dd8d9f000ea68e967b,

title = "Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.",

abstract = "In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.",

author = "D No{\"e}l and M Pelegrin and F Brockly and Lund, {Anders Henrik} and M Piechaczyk",

note = "Keywords: Animals; Antibodies, Monoclonal; Antibody Formation; Disease Models, Animal; Fibroblasts; Gene Therapy; Humans; Immunocompetence; Mice; Skin",

year = "2000",

doi = "10.1046/j.1523-1747.2000.00106.x",

language = "English",

volume = "115",

pages = "740--5",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "nature publishing group",

number = "4",

}

TY - JOUR

T1 - Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.

AU - Noël, D

AU - Pelegrin, M

AU - Brockly, F

AU - Lund, Anders Henrik

AU - Piechaczyk, M

N1 - Keywords: Animals; Antibodies, Monoclonal; Antibody Formation; Disease Models, Animal; Fibroblasts; Gene Therapy; Humans; Immunocompetence; Mice; Skin

PY - 2000

Y1 - 2000

N2 - In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.

AB - In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.

U2 - 10.1046/j.1523-1747.2000.00106.x

DO - 10.1046/j.1523-1747.2000.00106.x

M3 - Journal article

C2 - 10998153

SN - 0022-202X

VL - 115

SP - 740

EP - 745

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 4

ER -

Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this